Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prediction of ESA response by erythropoietin level and gene mutations in low-risk myelodysplastic syndromes
TCTR20200909001Recruiting
- Sponsor
- Ratchadaphiseksomphot Endowment Fund
- Start
- Jan 2020
- Countries
- 1
01
Overview
Open-label, single-arm trial in myelodysplastic syndrome (MDS), sponsored by Ratchadaphiseksomphot Endowment Fund. Primary endpoints: Hematologic response to ESA and Impact of gene mutations on ESA response. Started Jan 2020; status: recruiting.
02
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on TCTR20200909001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20200909001.